Cocrystal Pharma (NASDAQ: COCP) has highlighted promising clinical progress for its lead antiviral candidate, CDI-988, at the 9th International Calicivirus Conference in Banff, Canada. The company presented data from its Phase 1 study and detailed the drug’s mechanism of action, underscoring its potential to become the first oral treatment for norovirus, a widespread and underserved viral infection.
Strong Phase 1 Results
In its Phase 1 trial, CDI-988 demonstrated a favorable safety and tolerability profile, with no serious adverse events reported. Importantly, the compound achieved high exposure in small intestinal tissue, where norovirus infection occurs, reinforcing its potential effectiveness in targeting the virus directly at its source.
Broad Antiviral Activity
Laboratory studies showed CDI-988 has broad-spectrum activity against multiple norovirus genogroups, including GII.4 and GII.17, which are responsible for the majority of global outbreaks. These results provide strong preclinical validation for CDI-988’s ability to address diverse and evolving strains of the virus.
Advancing to Human Challenge Studies
The U.S. Food and Drug Administration has cleared Cocrystal’s Investigational New Drug (IND) application to initiate a Phase 1b human challenge study later in 2025. This trial will evaluate CDI-988 in both prevention and treatment settings, providing a key proof-of-concept milestone for the program.
Investor Implications
Norovirus represents a large, unmet medical need with no currently approved vaccines or treatments. A successful development path for CDI-988 could position Cocrystal as a leader in antiviral innovation, creating opportunities for value inflection and potential strategic partnerships.
Bottom line: With positive early safety data, broad antiviral activity, and FDA clearance to move into a human challenge study, CDI-988 is emerging as a potentially first-in-class therapy for norovirus. For investors, this progress strengthens confidence in Cocrystal’s pipeline and its potential to capture a significant market opportunity in infectious diseases.
The post Cocrystal Pharma Showcases CDI-988, a First-in-Class Oral Antiviral for Norovirus appeared first on PRISM MarketView.
